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ABSTRACT 
Parkinson’s disease (PD) is the second-most common neurodegenerative disease after 
Alzheimer’s disease. With 500,000 individuals currently living with Parkinson’s and nearly 
60,000 new cases diagnosed each year, this disease causes significant financial burden on the 
healthcare system - amassing to annual expenditures totaling 200 billion dollars; predicted to 
increase through 2050. The disease phenotype is characterized by a combination of a resting 
tremor, bradykinesia, muscular rigidity, and depression due to dopaminergic neuronal death in 
the midbrain. The cause of the neurotoxicity has been largely discussed, with strong evidence 
suggesting that the protein, alpha-Synuclein, is a key factor. Under native conditions, alpha-
Synuclein can be found localized at synaptic terminals where it is hypothesized to be involved in 
vesicle trafficking and recycling. However, its biochemical profile reveals a hydrophobic region 
that, once subjected to insult, initiates an aggregation cascade. Oligomeric species—products of 
the aggregation cascade—demonstrate marked neurotoxicity in dopaminergic neurons and 
illustrate migratory potential to neighboring healthy neurons, thereby contributing to progressive 
neurodegeneration.  
The current golden standard for PD diagnostics is a highly qualitative system involving a 
process-by-elimination with accuracy that is contingent upon physician experience. This, and a 
lack of standardized clinical testing procedures, lends to a 25% misdiagnosis rate.  Even under 
circumstances of an accurate PD diagnosis, the only treatment options are pharmacologics that 
have a wide range of adverse side effects and ultimately contribute to systemic metabolic 
dysfunction. Thus, the research presented in this thesis seeks to overcome these current 
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challenges by providing (1) a quantitative diagnostic platform and (2) a biomolecular 
therapeutic, towards oligomeric alpha-Synuclein.     
 Aim 1: serves as a proof-of-concept for the use of catalytic nucleic acid moieties, 
deoxyribozymes and aptamers, to quantify alpha-Synuclein in a novel manner and explore the 
ability to detect oligomeric cytotoxic species. The cost-effective nature of these sensors allows 
for continued optimization.  
Aim 2: serves to establish a potential therapy that can abrogate alpha-synuclein 
oligomerization and toxicity through use of a modified Protein Disulfide Isomerase (PDI) 
peptide when introduced to live cells treated to simulate pre-parkinsonian pathology.   
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CHAPTER ONE: INTRODUCTION 
Etiology of Parkinson’s Disease 
Parkinson’s disease (PD) is a progressive neurodegenerative disease with incidents making it the 
second most common neurodegenerative disease after Alzheimer’s disease1. The disease  
phenotype is characterized by any combination of four diagnostic features: resting tremor, 
bradykinesia, muscular rigidity and postural instability due to dopaminergic deficit in the 
nigrostriatal region of the midbrain2. Current epidemiological data reveals that, as of 2005, more 
than 4 million were diagnosed worldwide, with a 0.3% prevalence in the general population and 
a male:female ratio of 3:21. The general cause of PD is unknown and largely debated, as both 
idiopathic and genetic forms of the disease arise in the clinical setting. Diagnosis and treatment 
of PD are limited, likely due to the inherent difficulty in delineating several near-identical 
symptom profiles found in other neurodegenerative diseases3. Much attention in regards to 
targeted diagnostics and therapies has been turned to a key molecular hallmark of PD, alpha-
Synuclein (α-SYN), which exists as aggregated intraneuronal inclusions in the PD brain4. 
Clinical Diagnosis of PD 
As previously mentioned, the cause of PD is elusive, with early and/or prophylactic diagnosis 
remaining a challenge during pathogenesis5. Genetic screening is available but is only applicable 
in a limited number of cases6, excluding idiopathic conditions, which are more epidemiologically 
prevalent. It has been noted that environmental, genetic, and epigenetic influences can be 
responsible for an individual’s propensity to PD at varying ages in life. Typically, the disease 
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occurs infrequently under 40 years of age, coined familial PD. It is most prevalent in patients 
over 65 years of age, clinically denoted as idiopathic PD. In the United States alone, there exists 
an excess of 500,000 patients, with 60,000 new patients diagnosed yearly7.  
As mentioned above and described below, motor characteristics denote a symptomatic patient in 
the clinical setting.  
1) Bradykinesia is defined as the loss of speed in performing repetitive movements of 
extremities, and is easily confused with simple slowness encountered during 
advanced age. A subset of bradykinesia can include any combination of hypomimia, 
hypophonia, micrographia, and dysphagia (decreased or absent facial expression, 
diminutive vocal projection, diminutive handwriting, and difficulty swallowing, 
respectively)2. 
2) Resting tremor, otherwise known as parkinsonian tremor, is the presentation of 
subtle, rhythmic movements when the body is not engaged physically or mentally. 
The most notorious clinical example of resting tremor is known as “pill-rolling” in 
which the patient involuntarily rubs the flat of their pollex and index finger together 
in minute circular patterns8.  
3) Rigidity is classified as an abnormal increase in muscle tone during movement of the 
both flexor and extensor muscular analogs, in either the neck or extremities. This 
incongruity amongst muscle groups leads the patient to experience “cog-wheel” 
movements where movement in one muscle group will trigger simultaneous 
movement of another group that otherwise would not be integrated9.  
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4) Gait Impairment is the final and most identifiable symptom of a PD patient. Often, 
the patient will exhibit “anterior truncal flexion” whereby the upper body leans 
inward,  less than 20 degrees relative to normal. This is accompanied with shuffling 
footsteps where the feet of a patient will not undergo dorsal flexion or plantar flexion 
during walking. To conclude gait impairment, a physician will employ a “pull-test” to 
gage the individual’s ability to maintain a stable posture or observe a sort of 
“chasing” of their center of gravity10.  
In conjunction with the four motor criteria, patients will also exhibit non-motor 
symptoms linked to neuropsychiatric, autonomic, and sensory deficits such as anxiety, 
hyperlacrimation, insomnia, and hyposmia11. Such symptoms are often disregarded in the 
absence of motor deficits, which has the potential to lead to misdiagnoses and, as a result, 
imposes a large degree of physician-to-physician variability due to the strict clinical nature of PD 
diagnosis. Studies have shown that correct diagnosis of PD in cases where classic symptoms are 
absent is challenging for physicians. Autopsy data have shown 24% of individuals initially 
diagnosed with PD lacked specific hallmarks of the disease (i.e. Lewy Bodies) and actually had 
diseases more aptly classified as progressive supranuclear palsy, Alzheimer’s disease, or 
multiple system atrophy12. Furthermore, data suggest diagnoses can occur anywhere from two 
months to 18 years after symptom onset, with 5-25% of diagnosed patients having been 
misdiagnosed and receiving medication for a disease they did not in fact have13. Conversely, it 
has been reported that 20% of patients who received clean bills of health due to the lack of 
“gold-standard” symptoms, did in fact have PD3. The current state of diagnosis for PD, without a 
ubiquitous and quantifiable target, has proven to be imprecise.   
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Much attention has been turned to monitoring the depreciation of dopamine in the Substantia 
Nigra (SN), a key factor in PD responsible for the discordant fine-motor processes. For several 
decades, post-mortem analysis of the striatum (projected upon by the SN) has revealed a striking 
depletion of dopamine in PD patients (Figure 1). Through positron emission tomography and 
single-photon emission computed tomography (PET and SPECT, respectively), radio-ligands 
such as [99mTc]TRODAT-1 SPECT and [18F] DOPA PET are able to target dopamine 
transporters either at the pre- or post-synaptic termini. This allows physicians to quantify with 
high specificity the concentration of dopamine in the SN and subsequent discrimination between 
PD and non-degenerative diseases14. However, there is a major limitation to dopaminergic 
molecular imaging: the sensitivity and specificity of imaging is based on the previously 
discussed “gold-standards” of clinical PD diagnosis, which at this point are understood to be 
quite variable. As such, further expansion on current imaging protocols would be established on 
what is previously understood as a vacuous clinical foundation. Therein lies a continued need to 
establish biomarkers that can both reduce chances of misdiagnoses as well as provide substantial 
and quantitative data that distinguishes between Parkinson’s-like diseases such as non-Lewy 
Body dementia and non-degenerative tremor disorders. Patient samples such as blood or cerebral 
spinal fluid are of increasing interest as a timely means of detection. However, due to multi-
variable experimentation, these approaches are quire premature and therefore require more 
exploration15.   
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Current Clinical Treatment of PD 
To date, several interventions of PD, both pharmacological and surgical, exist to a semi-efficient 
degree, making therapeutics higher in terms of clinical competency when compared to 
diagnostics. However, a substantial amount of adverse effects arise from both, regardless of the 
strict guidelines physicians follow to ensure proper treatment. From the pharmacological 
perspective, subclasses include: Levodopa, Catechol-o-methyl-transferase (COMT) inhibitors, 
dopamine agonists, and non-dopaminergic drugs.16. 
 Levodopa (L-DOPA), or L-3,4-dihydroxy-phenylalanine, is a chemical analog of 
dopamine. Because dopamine has a terminal amine conserved from its amino acid precursor, 
tyrosine, its highly polarized dipole-moment inhibits the ability to penetrate the blood-brain-
barrier (BBB) and, as such, cannot be used as a drug with the aim of compensating for the 
decline of intrastriatal dopamine17. Levodopa, however, maintains its amino-acyl backbone and 
is able to permeate the BBB. After crossing the BBB, DOPA decarboxylase then reduces the 
carboxy terminus of levodopa to a secondary amine, yielding intracerebral dopamine. Despite it 
being the most popular, as well as potent pharmacologic available for PD, L-DOPA in itself can 
induce motor pathologies such as dyskinesias. L-DOPA is therefore in a constant state of debate 
regarding its clinical efficacy16. At times, a peripheral DOPA-decarboxylase inhibitor, carbidopa, 
enhances the drug’s potential by limiting the activity of DOPA-decarboxylase in regions of the 
body other than the brain. It has been reported that patients prescribed L-DOPA will typically 
experience motor deficits after five years of regimented L-DOPA, which leads some physicians 
to withhold L-DOPA therapies until deemed fit so as to postpone the onset of the adverse side 
effects. It has also been noted that early-onset PD, as well as genetic forms such as PARK2 and 
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PARK8, are especially susceptible to the development of L-DOPA-related motor deficits18. 
Countermeasures for the amelioration or prophylaxis of L-DOPA dyskinesias include titration of 
the dosage, additional medications, or even surgical intervention to place drug-secreting 
bioreactors in localized area of the brain.   
Catechol-o-methyltransferase (COMT) is an enzyme that is responsible for the 
degradation of catecholamines such as dopamine, norepinephrine, and epinephrine. In doing so, a 
catechol hydroxyl group is methylated, and subsequently converted to the metabolite, 
Homovanillic acid (HVA through the enzymatic activity of monoamine oxidase (MAO). HVA is 
excreted in the urine. The inhibition of COMT thus blocks the degradation of both endogenous 
dopamine and L-DOPA, thereby increasing the plasma concentration of L-DOPA and prolonging 
its activity, while reducing the aforementioned side-effects of L-DOPA-induced dyskinesias19. A 
stark drawback to certain COMT inhibitors is the necessitation of stringent clinical monitoring 
due to the hypervariable tolerability of the drugs. A 2007 study indicated that a 100 mg dose of 
COMT inhibitor three times daily increased hepatotoxicity, with liver transaminase levels almost 
three times the upper normal limit (UNL), in some cases20. With that, individuals prescribed 
COMT inhibitors are required to have liver enzyme monitoring approximately every two weeks 
for the first year of the regiment.  
Dopamine agonists are typically administered in the initial period of PD as they allow 
physicians to delay the use of L-DOPA and its adverse effects21. Dopamine agonists do not 
require further metabolic processing by the body and are able to bypass dopamine synthesis at 
the pre-synaptic termini22. Upon binding to D2 receptors, antiparkinsonian effects can ensue; 
however, engagement of the D1 receptor is also necessitated to mediate behavioral deficits. 
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Unfortunately, the overall ameliorative effects are quite modest with respect to the L-DOPA 
counterpart, and, as with COMT inhibitors, can involve a degree of hepatotoxicity from its 
pharmacokinetic profile.  
Non-dopaminergic pharmacologics include anticholinergics which have been shown to 
mediate symptoms in the early years of PD, and are often employed in patients of a younger 
demographic that display advanced motor impairment. To counter PD-induced behavioral issues 
such as depression, neurologists also prescribe anticholinergics that enhance pre-synaptic 
serotonergic, 5HT2 and 5HT3, receptors. Drawbacks to such medications include cognitive 
impairment and incontinence, further perpetuating the theme of non-specific means of PD 
treatment and the adverse side-effects implicated at the peripheral level23.  
Advents in molecular biology have yielded several in-trial biologics for restorative and 
protective properties at the midbrain. At the in vitro level, neurotrophic factors such as neurturin 
(NTN) and glial cell-line-derived neurotrophic factor (GDFN) have demonstrated prophylactic 
effects on the dopaminergic neurons by preventing cell-death24,25. This observation, however, 
was not at the patient level as intracerebroventricular injection of GDFN in a human trial led to 
severe dementia and anorexia without ameliorating the effects of PD. More recently, a twelve 
patient study involved stereotaxic implantation of an adeno-associated virus type 2 vector 
(AAV2-NTN) that utilized a patient’s transcription and translation machinery to produce 
intraputaminal NTN. This work showed an improvement in the Unified Parkinson’s Disease 
Rating Scale (UPDRS) by upwards of 20%. Further investment was made in the use of retinal 
pigment epithelial cells (hRPE), which are responsible for the production of L-DOPA in the 
retina. Stereotactic implantation of hRPE demonstrated symptom improvement in human 
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subjects, improving UPDRS by upwards of ~50%26. It should be noted, however, there are 
substantial drawbacks to the use of aforementioned technology. Stereotaxic surgery is an 
invasive procedure, and the exact location of injection varies from human to human, only 
conserved within several cubic millimeters based on the x,y,z coordinate system. Furthermore, 
the use of recombinant DNA or immortalized cells are topics of heated debate, requiring 
substantial amount of financial investment and insurance, FDA approval, and a timely 
exploration of methods to control the potential adverse side-effects on a systemic level.  
Alpha-Synuclein Mediated Molecular Pathogenesis 
Structure of Alpha-Synuclein 
A hallmark feature of PD is the intraneuronal presence of Lewy Bodies; cytoplasmic inclusions 
of aggregated α-SYN27 (Figure 2). This low molecular weight (14 kDa) protein is a subclass of 
synuclein proteins along with beta- and gamma-Synuclein, although its beta and gamma relatives 
are not associated with progressive neurodegeneration28. In non-pathological conditions, this 
protein is highly soluble and abundant in regions of the brain, predominantly in the presynaptic 
terminals of the neocortex, hippocampus, striatum, thalamus, and cerebellum. It is also found 
elsewhere in the body, such as liver and bowel, albeit at lower concentrations. Structural analysis 
reveals it is comprised of random coils in its natively unfolded state and can withstand 
temperatures of 110°C as well as highly acidic environments, leading scientists to postulate PD 
as prion-mediated pathogenesis29. Upon insult, soluble monomers undergo aggregation with the 
potential to inflict cytotoxic effects on neurons by compromising their membrane integrity. The 
140 amino acid sequence of α-SYN has been largely studied, and thorough analysis reveals the 
9 
 
presence of three conserved domains including 1) a highly conserved N-terminal repeat domain, 
2) a central hydrophobic domain, termed non-Aβ component (NAC) and 3) an acidic carboxy-
terminal domain (Figure 3).  
1) N-terminal Repeat Domain: consists of residues 1 through 65. This region has six 
copies of 11 imperfect amino acid repeats based on a “Lys-Thr-Lys-Glu-Gly-Val” 
consensus sequence that contributes to the formation of two alpha-helical structures30. 
The presence of both hydrophobic and hydrophilic R groups manifest into an 
amphipathic lipid-binding domain that allow this region to engage the negatively 
charged lipids of the phospholipid bilayer, constituting a membrane-associated 
construct31. It is believed that its lipid-associated interactions may potentiate α-SYN’s 
aggregative properties in neurodegenerative pathophysiologies. It is also within this 
region that two point mutations have been elucidated as precursors to autosomal 
dominant early-onset PD: Ala at position 53 to Thr (A53T) and Ala at position 30 to 
Pro (A30P). Both mutations confer a beta-sheet conformation that facilitates α-SYN 
oligomerization32.  
2) NAC domain: Residues 65-95, confer to the highly amyloidogenic region of the 
molecule. These amino acids are also deemed responsible for the protein’s ability to 
shift from random coil to β-sheet moiety, facilitating the genesis of amyloid 
oligomers, protofibrils, and fibrils characteristic of PD and Alzheimer’s disease33. 
3) Acidic Carboxy-Terminal Domain: Residues 96-140 are highly variable in sequence 
and length, however conserve highly negatively charged acidic amino acids34. This 
region does not contribute to higher-ordered secondary structures but nevertheless 
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confers a chaperone-like property to α-SYN35. Truncations of these residues have 
demonstrated significantly heightened aggregation potential. Several phosphorylation 
sites mediate the chaperone-like activity through involvement of tyrosine kinase as a 
putative anti-neurodegenerative property36. Post-mortem analysis of purified LBs 
illustrates the presence of full-length α-SYN in conjunction with fragments having 
truncated acidic carboxy-terminal domains37.  
Physiological Role of α-SYN 
Extrapolations based on the structural analysis of α-SYN are indicative of several physiological 
roles, although a definitive normative process has yet to be confirmed. It is believed that a major 
role utilizes the aliphatic N-terminal repeat domain to engage presynaptic neurons in vesicular 
neurotransmitter release38. Bovine studies suggest α-SYN as an inhibitor of phospholipase D2, 
which facilitates the hydrolysis of phosphatidylcholine to phosphatidic acid (PA). PA, a 
macromolecular phospholipid building block, constitutes vesicular bilayers implicated in 
exocytotic neurotransmitter secretion in conjunction with vesicle recycling and neurotransmitter 
turnover. Therefore, an inhibition of PA has an immediate inhibitory effect on the production of 
neurotransmitter packaging. In α-SYN knockout mice, stimulation of the substantia nigra pars 
compacta results in an exhaustive release of dopamine from pre-synaptic terminals, suggesting a 
negative regulatory role for α-SYN to conserve dopamine reservoirs39.  
α-SYN’s acidic carboxyl-terminal domain and various phosphorylation sites therein have 
substantiated the notion of an inherent chaperone-like quality to inhibit protein aggregation and 
assist in the re-folding of non-native proteins. Approximately 40% of α-SYN is homologous to 
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the molecular chaperone 14-3-3, which is abundant in the soluble protein fraction of the brain. 
However, 14-3-3 is detected in post-mortem analytes of LB’s extracted from the SN. With that, it 
is hypothesized that α-SYN infarcts 14-3-3’s ability to alleviate aggregation-induced 
cytotoxicity, ultimately compromising the cellular integrity40.  
α-SYN Pathogenesis 
As previously mentioned, PD is likely the result of imposed dopaminergic cytotoxicity due to the 
presence of intracytoplasmic inclusions of α-SYN. α-SYN, otherwise monomeric in a non-
pathological state, forms insoluble higher-order aggregates that likely compromise the integrity 
of the plasma membrane leading to progressive neurodegeneration (Figure 4). In vivo models 
support this hypothesis by having demonstrated that the addition of aggregated, pre-fibrillar 
forms (PFF) of α-SYN induced cell-death after ~120 days of inoculation. Also discovered was a 
self-propagating cascade of wild-type α-SYN aggregation in adjacent cells, illustrated by the 
presence of intracellular punctations of α-SYN via immunocytochemistry29. At the mammalian 
level, stereotaxic injection of α-SYN PFFs in-vivo demonstrated extreme toxicity and synaptic 
impairment in rat models with the presentation of PD-like symptoms. The mechanism by which 
α-SYN undergoes insult and subsequent aggregation has therefore been a great focal point for 
PD etiology. Two competing proposals for aggregation include 1) malfunctions in the ubiquitin 
proteasome system (UPS) and 2) oxidative stress induced by free radicals and reactive oxygen 
species (ROS).  
1) UPS is the primary biochemical mechanism by which cells degrade and recycle both 
normal as well as abnormal intracellular proteins through a two-step signaling 
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cascade. A protein targeted for degradation will be acted upon by several ubiquitin-
conjugating enzymes, through which interaction with the 26S proteasome will 
occur41. Interaction and recognition of the ubiquitin tags induces ATP-dependent 
proteolysis within the 20S core cylindrical unit, releasing small peptide fragments 
from the 19S cap to be further degraded in the cytosol via transaminases and 
transpeptidases42. The cascade is completed upon release of reusable ubiquitin 
components. Failure or downregulation of the UPS can cause an intracellular 
congestion of proteins intended for degradation and is implicit in the beginnings of 
neurodegeneration. Post-mortem analysis of the Substantia Nigra pars compacta LBs 
reveals the presence of ubiquitin polymers as well as fragments of the 26S 
proteasome. Biochemical analysis reveals proteins tagged for degradation bear 
ubiquitin tags, suggesting that poly-ubiquitination contributes to an inefficacious 
degradation pathway and subsequent PD pathogenesis43. 
2) The presence of oxidants has been well established as a method by which protein 
insult occurs. In vitro, it has been demonstrated that exposure of α-SYN to hydrogen 
peroxide and iron facilitates the aggregation of higher-ordered structures and 
formation of cytotoxic intermediates44. In a process coined the Fenton effect, cultured 
cells treated with traces of ferrous chloride demonstrate a heightened aggregation 
potential evident through Western blotting, immunocytochemistry, and cytotoxicity 
assays. Similar results are seen through use of hydrogen peroxide with the added 
effect of ROS-mediated mitochondrial dysfunction and cell death45. Studies involving 
mutated α-SYN (A53T, S42Y, A30P) illustrated a hyper-susceptible aggregation 
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response to oxidative species. The proposed mechanism by which oxidation-induced 
aggregation in PD occurs involves the chemical nature of dopamine. An inherent 
free-radical generator, as well as principal neurotransmitter in the SN, dopamine’s 
reactive chemical nature is compounded by free radical-generating iron which 
accumulates in neurons with advancing age, and substantiates a likely hypothesis as a 
pathogenic mechanism46. Advances in studying this process in vivo are being made to 
avoid the commonly used potent environmental toxins MPTP, Paraquat, and 
Rotenone, which induce neuronal death faster than LB formation47.  
While a definitive physiological role and mode of pathogenesis remains speculative in 
relation to the biochemical properties of α-SYN, the distinction between the monomeric and 
aggregated ultrastructure potentiates a clinically applicable biomarker for LB-related 
synucleinopathies such as PD. Researchers have applied antibody-based detection methods 
(ELISA, dot blots, etc.) to quantify α-SYN from patient samples. However, because antibodies 
are sequence-specific, differentiation between monomeric and oligomeric species has proven 
difficult. Recent advancements in oligonucleotide chemistry suggest small DNA constructs, or 
aptamers, can be used to identify macromolecules in an antibody-like fashion with the added 
benefit of distinguishing between polymorphic species. 
Aptamers 
Aptamers are receiving a significant amount of scientific exploration at the academic and 
industrial level as a class of functional nucleic-acid compounds with wide-scale applications 
targeted toward the clinical setting. Aptamers are composed of synthetic ssRNA or 
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ssDNA,which, due to intra-nucleic acid hydrogen bonding, achieve higher-ordered secondary 
and tertiary structures that confer a functional “lock-and-key” property to specific substrates in 
an antibody-like fashion48 (Figure 5). A functional aptamer ranges in size from ~20-100 nt, 
comparatively 20-25 fold smaller than the monoclonal antibody analogs, allowing for an 
increased penetrable ability across a variety of biological membranes and barriers such as the 
Bowman-Glomerular Capsule interface49. Furthermore, these moieties are nucleic acid polymers 
rather amino acid derived, reducing the chance of immunogenic response in vivo. Unlike 
antibodies, can distinguish between structural variants of proteins such as monomers and 
oligomers, whole-cells, or tissues; qualities that make aptamers substantial technology for use in 
clinical applications such as diagnostics, therapeutics, or synergistic “theranostics”50. 
Synthesis 
Aptamer synthesis was well established in 1990. However translational applications were not 
possible until recently when intellectual property patents on the mode of synthesis expired, 
leading to a surge of aptamer-based research. Biochemists Tuerk and Gold coined the process 
Systematic Evolution of Ligands by Exponential enrichment (SELEX) as they sought to select a 
library of RNA ligands that interacted with T4 DNA Polymerase51 (Figure 6). This iterative 
process begins with a randomized library of oligonucleotides, or “oligos” linked to a ubiquitous 
priming region. The oligos are heated in folding buffer that contains 1 mM MgCl2 to 95°C to 
denature the oligos and disrupt randomized intramolecular binding. The solution is then allowed 
to cool to room temperature at approximately 1°C per minute, which through Mg2+ cofactor, 
creates a functional aptamer by allowing the oligo to self-anneal according to the most 
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energetically favorable secondary or tertiary structure. The randomized aptamers are then 
incubated with target antigens as well as counter-selection compounds52. Those sequences that 
interact with counter-selection compounds are discarded while those that demonstrate binding to 
the target compound are amplified via PCR or RTPCR (for RNA moieties) with primers that 
anneal to the ubiquitous priming regions in the oligo library. This selection and amplification 
process is then repeated 10-20 times. Final selection will yield several aptamers with conserved 
sequences but variable dissociation constants as determined by surface plasmon resonance. This 
process can also be carried out using live cultured cells as a de novo process through which novel 
biomarkers can be established for specific cell types. Advantages of SELEX compared to 
animal-mediated antibody production include efficient production scaling, reduced production 
time, and a predictable chemical nature that allows for homogenous conjugation to fluorophores, 
quenchers, and drug cargo50. Furthermore, aptameric sequences can be adapted for a DNA-based 
enzymatic analyte detection system, or deoxyribozyme, to increase sensitivity and improve limits 
of detection. 
Deoxyribozyme Sensors 
Deoxyribozymes (Dz) are a class of novel synthetic oligonucleotide catalytic moieties that can 
be used in vitro to detect specific analytes including: metals, small molecules, and nucleic acids, 
with lower limits of detection than traditional means. This is established through Dz’s enzyme-
kinetic properties, which allow for signal accumulation and optimization based on incubation 
temperature, construct concentration, and incubation time.  
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 Kolpashchikov et al have been developing binary Dz sensors (BiDz) for the detection of 
polymorphic Mycobacteria DNA fragments as a means of a small-scale, affordable, and 
technologically simple diagnostic aid53. In their design, two non-natural DNA strands hybridize 
to either RNA or DNA fragments of M. tuberculosis, through traditional base pairing. Upon 
hybridization, a catalytic loop is formed through which phosphodiester cleavage of a Black Hole-
RNA-Fluorescein sequence substrate (F_sub) is permissible. This cleavage allows for detection 
via fluorimetry at 517 nm (Figure 7). The technology allows for 1) highly sensitive and 2) 
specific mode of detection, both of which are inherent requirements for biosensors: 
1. Because this system adheres to traditional enzyme-kinetic laws, the sensitivity 
of BiDz to the target antigen or analyte can be optimized to achieve 
significant detection even in low abundance (pM or fM) by altering the 
concentration of BiDz constructs, the concentration of F_sub, incubation time, 
and temperature of incubation (30°C, 37°C, 55°C, 65°C). This establishes a 
signal amplification feature required to achieve a robust limit of detection 
(LOD), without PCR-based amplification methods. 
2. The BiDz system reduces the occurrence of non-specific interactions due to 
the necessitation for both constructs to be sufficiently interacting with analyte 
in order to establish a functional catalytic core. This prevents weak 
interactions from contributing to signal production as may be the case with 
traditional fluorescent labeled probes54.  
To further improve LOD, Kolpashchikov et al has communicated a three-dimensional 
DNA scaffold, or DNA antenna tile-associated Dz sensor (Figure 8). With this, nine 
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oligonucleotide sequences with intrinsic self-complementarity are annealed to form a planar 
“tile”, upon which one of the two BiDz, and a “hook” sequence, which is partially 
complementary to each of the nine scaffolding sequences and partially complementary to the 
F_sub sequence or a modified aptamer sequence, are also annealed. This is an adaptation of the 
Chou model, wherein proteins can “channel” substrate to the active sites of the protein to 
increase diffusion-controlled catalysis and product formation. The hook sequences will therefore 
draw F_sub molecules out of solution toward the catalytic BiDz site and increase signal output, 
thereby broadening the LOD. Furthermore, the intricate scaffolding system of the Dz tile allows 
for the caging of drug cargo; conferring both diagnostic and therapeutic properties to this 
technology. A final Dz configuration includes aptamer Dz systems wherein an entire aptamer 
sequence is linked to each catalytic segment (Figure 9). Because of the ease of synthesis of these 
oligonucleotides (identical to oligonucleotide primer synthesis and purification), as well as the 
ubiquitous nature of the catalytic and tile sequences, one needs to simply supplement their 
desired sequence for the analyte binding arms to make use of the Dz systems. Although the 
BiDz, and Tile-BiDz systems have shown success for detecting nucleic acids, there are no known 
studies to date for the detection of protein analytes. However, with much advancement in 
aptamer-mediated protein detection, their use in Dz systems is imminent55.  
In-Vivo Applications 
Aptamers intended for in vivo applications must be chemically modified to withstand dynamic 
biological conditions not otherwise encountered in in vitro assays. A drawback to aptamer 
chemistry is degradation of the uncapped 5’ and 3’ termini upon interaction with exonucleases. 
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Furthermore, the phosphodiester backbone in pyrimidine residues can be targeted by 
ribonucleases, leading to internal degradation and loss of functional conformation. However, 
through the use of modified nucleotides, the stability of aptamers for in vivo studies can be 
efficiently, and cost-effectively, ameliorated. Inverted 2’-o-modified pyrimidine nucleotides such 
as 2’-amino pyrimidines and 2’-fluoro pyrimidines render endo/exonucleases catalytically 
inactive56. It is imperative that inverted bases as well as high molecular weight cargos be 
incorporated into the oligo library before SELEX as the modifications can alter dissociation 
constants or even specificity due to intramolecular interactions conferring altered Gibb’s free 
energies and conformations57.  
 The first aptamer to receive FDA approval occurred in 2004. To date several aptamers 
have approached clinical trial as modes of molecular imaging, diagnostics, and therapeutics. 
Popular fields of application include cancer therapy and arterial heart disease. ARC1779 was 
developed as a DNA aptamer selected for interaction with von Willenbrand (vWF) factor. 
Binding to vWF imposes an electro-repulsive force that inhibits ligand interaction with platelet 
membrane receptors. This then hampers the arterial thrombogenic cascade and formation of 
atherosclerotic plaque deposits, which could serve as a means of mediating coronary artery 
disease58. A similar mechanism is employed in cancer therapies wherein ARC1905, an RNA 
aptamer, binds complement component 5 (C5) and inhibits formation of the Membrane-Attack 
Complex (MAC). Absence of the MAC leads to down regulation of cell lysis and stunting of 
vascular-endothelial growth factor, hampering tumor angiogenesis and metastasis. Areas of 
interest such as cancer and vascular pathologies are applicable for aptamer studies due to the 
relative ease of access to targets as well as little variability among antigens59.  
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Further advancements in aptamer technology and synthesis have led to the development 
of highly functional aptamer probes that exhibit intrinsic activation properties upon interaction 
with their targets. TLS11a-GC was developed as a DNA aptamer via whole-cell SELEX and is 
able to recognize entire hepatocellular carcinoma cells. Utilizing aptamers’ intrinsic base-pairing 
principle, scientists successfully incorporated the anticancer drug Doxorubicin (DOX), which 
intercalates DNA, with an aptamer targeting only cancerous tissue. Therefore, instead of 
administering DOX systemically, which has had implications of induced cardiomyopathy, the 
drug can be delivered within the aptamer and released upon target-specific interaction60. 
Similarly, Activatable Aptamer Probes (AAP) are synthesized to have a fluorophore and 
quencher in close proximity when in the unbound state. Upon binding to their targets, a 
conformational shift induces dissociation of the quencher, permitting excitation and emission of 
the fluorophore. An interdisciplinary field, coined theranostics, utilizes this technology as a 
means of both diagnostics and therapeutics in the form of a chimera. Specifically, upon target 
binding and dissociation of the quencher in AAPs, the fluorescence emission can be used as a 
molecular imaging moiety, but also an excitatory frequency to a nearby substrate such as gold 
nanoparticles (AuNPs). Excitation of the AuNPs results in an immediate release of localized 
thermal energy used to destroy cancerous tissue in a controlled fashion without damaging the 
nearby healthy tissue, or photothermal therapy (PTT)61.  
Within the past five years, a considerable amount of study has been invested with the aim 
of surmounting the limitations to aptamer-based neurodegenerative diagnostics and therapeutics 
including: 
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1) Biomarkers for neurodegenerative diseases are often higher ordered structures 
of peptides that are nevertheless found in monomeric states in non-pathoogical 
conditions and therefore are composed of identical chemical sequences that 
must be differentiable by the molecular probe 
Ikebukuro et. al has demonstrated the production of aptamers selected for oligomeric α-SYN 
only. Using the typical SELEX scheme, the aptamers were counter-selected against monomeric 
and fribrillar forms, so as to enable researchers to detect the presence of cytotoxic species before 
LB production and subsequent neurodegeneration occur. Biochemical analysis via TfT analysis 
suggests aptamers T-SO517 and T-SO606 produce detectable responses against immobilized α-
SYN only when TfT intensity surpasses 1000 A.U., indicating the presence of higher-ordered 
species. Aptamer T-SO508, while showing the strongest reaction to oligomeric α-SYN, also 
detected A due to the conserved beta-edge conformation. However, because this type of motif 
is present in a wide variety of proteins (IgG, CRP, albumin), a sufficient negative selection is 
necessary to produce highly specific probes for use in physiological environments52.  
2) The blood-brain-barrier (BBB) inhibits upwards of 80% of polar, charged 
molecules such as DNA 
The BBB is a major hurdle in diagnosing and treating neurodegenerative diseases. While several 
drugs and probes have shown promise at the neurological level, achieving their final destination 
in a non-invasive manner leaves room for improvement62. In 2014, Freskgard et. al demonstrated 
increased brain penetration of a therapeutic monovalent antibody for Aβ plaques (mAb31) 
achieved through monovalent engagement of the Transferrin receptor (TfR). Engagement of this 
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receptor at the BBB microvasculature allows for receptor-mediated transcytosis through the 
polarized endothelium, delivering cargo through the abluminal region into the cerebral 
parenchyma. Within 15 minutes, intravenous injection of the antibody chimera displayed marked 
penetration and plaque decoration. Approximately 4.5 months post-treatment of the PS2APP 
amyloidosis mouse model, there was an increased therapeutic effect in the reduction of plaques 
8-16 µm2 when compared to treatment without TfR engagement. This study shed light on the 
significance of receptor engagement for non-invasive shuttling across the BBB. However, 
antibody-based reactions of the TfR and parenchymal delivery can impose several disadvantages 
such as intra-endothelial lysosomal sorting and degradation upon divalent interaction of the 
receptor or an induced immunogenic reaction as a result of the large peptide-based IgG 
molecules63. Beltram et. al utilized a similar concept of TfR engagement as a means of CNS 
delivery but employed the anti-TfR aptamer ATTO 633 as opposed to antibodies. Because 
aptamers display monovalent modes of binding, there is a reduced chance of lysosomal sorting at 
the BBB endothelium64. 
3) Biomarkers for neurodegenerative diseases, such as α-SYN aggregates, are 
intracellular inclusions, therefore aptamers must be capable of freely accessing 
the plasmalemma 
Because α-SYN deposits are intracellular, another hurdle to engage the LB for diagnostic and/or 
therapeutic purposes is the ability and efficiency by which molecular probes can diffuse through 
the neuronal plasma membrane without imparting their own degree of cellular damage after CNS 
access. Further metabolic differences between neurons and the polarized endothelium of the 
BBB necessitate conflicting functions of the molecular shuttle. In endothelium, or BBB 
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interface, maintenance in the transport vesicle is imperative to be completely transcytosed across 
the BBB. However, at the neuronal interface vesicular release into the cytoplasm is required for 
interaction with the cytosolic target in a process dubbed endosomal release. Battaglia et. al 
illustrated engagement of Low Density Lipoprotein Related Protein 1 (LRP-1) receptor 
facilitates the aforementioned requirements. pH-sensitive polymersomes containing nucleic 
acids, coated with LRP-1 ligand Angiopep-2, triggers transcytosis at the BBB endothelium. Once 
in the parenchyma, these constructs are then able to engage in traditional endocytosis by the 
neurons without intracellular lysosomal sorting and circulate freely in the cytoplasm of the 
neurons.  Advancements in aptamer- and nanotechnology have established several modes by 
which diagnostic or therapeutic aptamers can self-facilitate target engagement with minimally 
invasive and diminutive toxic effects in vivo65. It can be understood, however, that the 
significance of the information provided to a patient by a quantitative diagnostic is contingent 
upon the therapeutic alternatives available thereafter. Because of this, a target-specific 
therapeutic that obstructs neuropathy at the mechanistic hallmark of PD progression—α-SYN 
aggregation—is necessary. Recent discoveries with Protein Disulfide Isomerase are suggestive 
of a potential biologic that ameliorates α-SYN aggregation and thus lends a therapeutic route of 
exploration. 
Protein Disulfide Isomerase 
Protein Disulfide Isomerase (PDI) is a ubiquitously expressed 55 kDa thioreductase, with 
oxidoreductase, isomerase, and chaperone-like properties66. A Lys-Asp-Glu-Leu (KDEL) 
retention sequence localizes PDI predominantly in the endoplasmic reticulum (ER) where post-
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translational packaging, modification, and folding occur. However, PDI has been located in the 
intracytoplasmic and extracellular regions as well67,68. PDI is responsible for the formation, 
removal, and rearrangement of covalent disulfide bonds as part of the tertiary folding process of 
nascent proteins69. Several pathophysiological manifestations, such as cancers, cardiovascular 
disease and amyloidogenic neurodegenerative disease, are corollary with PDI dysregulation and 
loss of proteostasis70.  
Structure of PDI 
PDI consists of four highly conserved domains with an abb’xa’ arrangement followed by a 
highly acidic C-terminal extension (Figure 10). The two catalytic (a & a’) domains are separated 
by the non-catalytic (b & b’) regions as well as the (x) loop linker71. Each catalytic domain 
consists of conserved Cys-Gly-His-Cys (CGHC) active site sequences that confer oxidoreductase 
activity through the cysteine residues. Each CGHC active site, when in the ER environment, has 
high reducing capabilities for disulfide groups, which lend to PDI’s high oxidative potential72. 
The domain responsible for the chaperone function of PDI so as to inhibit protein aggregation 
and/or targeting of misfolded proteins for degradation remains unknown. It is hypothesized that 
this domain contains hydrophobic residues which allow for interaction with aggregated protein 
targets as the main substrate-binding site73.  
Function of PDI and the Unfolded Protein Response 
The two major functions of PDI include 1) oxidoreductase activity, which can either oxidize, 
reduce, or isomerize disulfide bonds formed during post-translational folding, and 2) chaperone 
activity to block hydrophobic interactions of aggregated proteins and promote degradation of 
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terminally misfolded proteins or protein accumulation via the Unfolded Protein Response 
(UPR)74. 
1. The catalytic (a & a’) domains operate independently of one another. According to 
Xu et. al, disruption of any one of the two CGHC active sites reduces oxidoreductase 
activity by 50%, where disruption of both active sites reduces oxidoreductase 
function altogether. The ability of PDI to alter disulfide bonds relies on the redox 
state of both PDI (influenced by electrochemical properties of the ER), as well as the 
target substrate73. 
2. The chaperone activity of PDI is conferred through the (b’) domain. This site, rich in 
hydrophobic amino acids, is the primary substrate binding site which through 
hydrophobic interaction maintains a high-affinity interface with complementary 
regions of protein aggregates. Because the enzyme-substrate complex is maintained 
via hydrophobic van der Waals forces, the specificity of PDI is vast73. 
The Unfolded Protein Response (UPR) is the highly concerted process by which ER 
stress is monitored and ameliorated through several feedback pathways75. The UPR can 
discriminate between moderate and therefore abrogative ER stress generated through misfolded 
protein accumulation, as well as excessive or chronic ER stress which will prompt pro-apoptotic 
signal cascades76. ER stress sensors are tethered to the ER chaperone BiP. Under stressed 
conditions, the large concentration of misfolded proteins in the ER outcompete stress sensors for 
hydrophobic interaction with BiP, resulting in activation77. Three well characterized ER stress 
sensors which regulate UPR include 1) PKR-like endoplasmic reticulum kinase (PERK), 2) 
activating transcription factor 6 (ATF6), and 3) inositol-requiring kinase (IRE1). The 
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combinatorial effect of these sensors under moderate ER stress is ameliorative in that they inhibit 
translation, promote physical expansion of ER volume, and lead to transcriptional activation of 
ER chaperones such as PDI.  
1. PERK: upon activation, PERK leads to phosphorylation of eukaryotic translation 
initiation factor 2α (eIF2α). Phosphorylation of eIF2α inhibits ubiquitous translation, 
yet confers selective translation of transcription factor ATF4 mRNA; AFT4 then 
translocates to the nucleus and initiates the production of PDI and other ER-localized 
chaperones78. 
2.  ATF6: ATF6 is transported from the ER to the Golgi apparatus and cleaved to form 
ATF6 fragment (ATF6f) which then translocates to the nucleus and activates 
transcription of PDI and ER-associated degradative (ERAD) enzymes which subject 
terminally misfolded proteins to degradation79. 
3. IRE1: upon dimerization and phosphorylation, IRE1 activates and degrades mRNA 
with an ER signal sequence so as to prevent further accumulation of nascent proteins 
within the ER following translation. Furthermore, IRE1 splices the mRNA encoding 
transcription factor X-box binding protein 1 (XBP-1) which results in a frameshift 
mutation to the mRNA that allows for the production of a functional transcription 
factor. Newly synthesized XBP-1 moves to the nucleus and initiates the production of 
ERAD enzymes, and phospholipids. These effects enlarge the ER and allow for an 
increased quantity of ER chaperones80,81.  
Under chronic conditions of ER stress, as encountered through extensive accumulation of 
protein aggregates, the UPR stress signals convert from pro-protective to pro-apoptotic 
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cascades82. Prolonged activation of PERK leads to the production of C/EBP-homologous protein 
(CHOP), which subsequently inhibits the BCL-2 survival protein and simultaneously activates 
Bcl2-interacting mediator of cell death (BIM). These actions concertedly trigger the BAX- and 
BAK- dependent mitochondrial apoptotic caspase cascade83. Interestingly, CHOP has been 
demonstrated to contribute to conditions of oxidative stress by abstracting electrons from 
chaperones such as PDI and converting diatomic oxygen to hydrogen peroxide80.  
Redox Stress, PDI, and Neurodegenerative Disease 
Reactive oxygen species (ROS) and reactive nitrogen species, in particular, have been reported 
to render PDI afunctional. Excess nitrosative stress can lead to a post-translationally S-
nitrosylated form of PDI (SNO-PDI). The addition of the nitric monoxide to the thiol groups of 
each CGHC active site inhibit the oxidoreductase capabilities of the (a & a’) domains; ultimately 
leading to an increase in misfolded proteins84. Uehara et al demonstrated a colocalization of 
SNO-PDI and α-SYN within LBs of post-mortem brains from PD patients. It should be noted, 
however, that the general chaperone mechanism of PDI is largely uncharacterized as is its 
vulnerability to redox stress. Because oxidative and nitrosative stress-mediated apoptosis is a 
prominent finding in cases of neurodegenerative disease and contributes to further protein 
aberrance, there appears to be a cyclical phenomenon by which protein misfolding contributes to 
ER stress and induces pro-apoptotic cascades that result in oxidative damage, thereby inhibiting 
chaperone molecules which in turn leads to further protein misfolding and ultimately progressive 
neuronal death. 
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This literature review lends insight into the etiology of PD, the molecular mechanism of 
PD pathogenesis, as well as the clinical insufficiencies that make PD the second-most common 
neurodegenerative disease worldwide. Furthermore, a review of DNA nanotechnology and 
molecular cell biology potentiate novel resolutions to the undeniable lack of quantitative 
diagnostics and target-specific therapeutic options for PD. This thesis contains a two-fold 
translational research study using 1) aptamer-based Dz systems to serve as an oligomeric α-SYN 
detection platform for early PD diagnosis, and 2) PDI to abrogate oligomeric α-SYN-mediated 
neuropathy as a potential gene therapy for PD. 
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CHAPTER TWO: APTAMER-BASED DEOXYRIBOZYME DETECTION 
OF OLIGOMERIC α-SYN 
Materials and Methods 
Aptamer Dot-Blot Detection of Oligomeric -SYN 
The Aptamer used, as reported by Ikeubkro et. al T-SO508, was purchased from GeneLink 
(Hawthorne, NY) biotinylated at the 5’ end and purified via gel purification. The aptamer was 
reconstituted in Tris-HCl with EDTA pH 7.5 to a stock concentration of 200 µM. At the time of 
use, T-SO508 was brought to a working concentration of 5 µM in PBS-HCl pH 7.5 
supplemented with 1 mM MgCl2. The solution was aliquoted into thin-walled PCR tubes and 
incubated at 99°C for five minutes in a thermal cycler to denature and anneal the oligonucleotide. 
After five minutes the sample was allowed to cool to room temperature for approximately one 
hour in the sealed heat block. 
 Recombinant pre-fibrillar form (PFF)— oligomeric—and monomeric α-SYN, kindly 
provided by John’s Hopkins, were diluted to 1 mg/ml in PBS and sonicated at 20Hz for one 
minute with 0.5-second pulses. After sonication, working samples of 1.0, 0.75, 0.5, and 0.25 
mg/ml were prepped via serial dilution with PBS. 
 A PVDF membrane was activated in 100% Methanol for 30 seconds followed by a five-
minute wash in water with shaking. A 2 µl aliquot of each monomeric and PFF α-SYN was 
blotted in the reaction zone and the membrane was allowed to dry for fifteen minutes. The 
membrane was then blocked in non-protein based blocking solution (LI-COR Biosciences 
Lincoln, NE) diluted to a 1X concentration with PBS plus 0.1% Tween-20 for one hour at room 
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temperature with rocking. After blocking the membrane was washed three times in 0.1% PBS-T 
wash buffer for ten minutes each. Annealed T-SO508 was added directly to each reaction zone 
and allowed to incubate in a humidified chamber at room temperature for approximately one 
hour. Using 0.05% PBS-T spiked with 1 mM MgCl2, the membrane was washed three times for 
ten minutes each.  
 For colorimetric development, an Avidin-Biotin-HRP Complex (ABC) kit (Vector 
laboratories Burlingame, CA) was used. The ABC reaction mix was incubated with the 
membrane for no more than five minutes, followed by three fifteen minute washes with wash 
buffer and vigorous shaking. To develop, 2,2-diaminobenzidine substrate (DAB) (Vector 
laboratories Burlingame, CA) was added for immediate colorimetric development. 
After confirmation of reactivity of the reported aptamer sequences to the α-SYN of use via dot 
blot, several sequences were selected and modified for deoxyribozyme (Dz) application 
(Table1).  
Deoxyribozyme Detection Assays for Oligomeric -SYN  
Traditional BiDz, Tile Dz, and Aptamer Dz oligonucleotides were designed and provided 
(Integrated DNA Technologies Coralville, IA) kindly by D. Kolpashchikov of University of 
Central Florida, Department of Chemistry. Each sensor was purified through standard desalting 
(SD). The fluorogenic substrate (F_sub) (TriLink Bio Technologies, Inc. San Diego, CA) was 
purified via high-pressure liquid chromatography (HPLC) used at a working concentration of 
200 nM per reaction. BiDza and BiDzb were used at working concentrations of 2 nM and 50 nM, 
respectively. Aptamer Dza and Aptamer Dzb were used at working concentrations of 2 nM and 
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50nM, respectively. In cases involving use of the tile-associated Dz sensor, 100 nM of each of 
the nine tile strands (T1-T9) were combined in reaction buffer and annealed by incubating in a 
100°C water bath followed by gradual cooling overnight. The annealed tile was used at a 
working concentration of 2 nM per reaction mix. All assay reactions took place in Dz reaction 
buffer (50 mM HEPES, pH 7.4, 50 mM MgCl2, 20 mM NaCl, 0.03% Triton X-100, and 1% 
DMSO) at a final volume of 60 μl. 
 Recombinant PFF was prepared as previously mentioned in working stocks of 100 μM 
and 10 μM. To determine the LOD of each class of sensor for α-SYN detection, a titration curve 
was used consisting of 1 nM, 10 nM, 20 nM, 50 nM, and 100 nM PFF. Analytes were incubated 
with each class of sensor for 1.5 and 18 hours at 30°C. Fluorescence values were obtained at an 
excitation/emission setting of 485/517 nm (Perkin-Elmer LS-55 spectrometer Waltham, MA).  
Deoxyribozyme Specificity Assay to Oligomeric -SYN 
BiDza and BiDzb were used at working concentrations of 2 nM and 50 nM, respectively. 
Aptamer Dza and Aptamer Dzb were used at working concentrations of 2 nM and 50nM, 
respectively. The annealed Tile Dz was used at a working concentration of 2 nM per reaction 
mix. Dzb was used at a concentration of 50 nM per reaction mix. Each of the three sets of sensor 
were incubated with 100 nM PFF, and 100 nM of monomeric α-SYN in parallel with a 26 M 
thrombin negative control for 18 hours. Fluorescence values were obtained again at an excitation 
emission setting of 485/517 nm. 
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Results and Discussion 
To explore the biologically compatible diagnostic potential for detecting oligomeric α-SYN, 
novel Dz sensors were utilized detect structure-specific α-SYN. The aims of using 
deoxyribozyme systems being: 1) to achieve lower limits of detection by manipulating the 
enzyme-kinetic properties of the Dz sensors and 2) to distinguish between pathological and 
native α-SYN structures. This will lay the foundation of a clinical neurological screening method 
that is standardized for early PD detection through use of a sensitive, specific, and quantitative 
diagnostic system with a quick and cost-effective turnaround time.  
Colorimetric Dot Blot Revealed Aptamer Specificity to Oligomeric α-SYN 
Aptamer sequences as communicated by Ikebukro et al were adapted for Dz design. Sequence T-
SO508 was selected based on its reported affinity and specificity so as to ensure the reported 
sequences were compatible with the recombinant α-SYN of use. To test the preliminary 
specificity of T-SO508 before proceeding with Dz adaptation, a colorimetric dot blot was 
performed to probe for immobilized recombinant α-SYN (Figure 11). This system demonstrated 
selectivity to the oligomeric (PFF) species of α-SYN, without cross-reactivity to the monomeric 
species. However, 0.5 μg of immobilized oligomeric α-SYN (18 nM) was not significantly 
detectable even with the 4-fold amplification properties of the ABC system and considerably 
high concentration of aptamer probe as compared to Dz sensor concentrations.  
Binary Dz, Tile Dz, and Aptamer Dz Limit of Detection of α-SYN 
Raw (Figure 12) and adjusted (Figure 13) fluorescent values for each Dz system at 1.5 and 18 
hours of incubation with -SYN were compiled. Error bars are representative of the standard 
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deviation of each trial.  It was evident that the 1.5-hour incubation produced no statistically 
significant means of detection, however an 18-hour incubation period did in fact produce a 
discernable signal sufficient for quantification. To determine the limit of detection of each 
system, the respective raw values were then plotted to generate a line of best fit (Figure 14). 
Using the formula 
3.0ℴ−𝑏
𝑚
 , the LOD for BiDz, Tile Dz, and Aptamer Dz were calculated to be 
14.67 nM, 12.45 nM, and 7.95 nM, respectively. The Dz detection system demonstrates greater 
efficiency at detecting -SYN by requiring nearly 100 times less sensor than traditional methods 
such as immobilized blotting and colorimetric development. The next phase of this work will 
consist of performing kinetic assays to determine the optimal incubation time between 1.5 and 18 
hours, as it was previously demonstrated that 1.5 hours is insufficient required for significant 
signal accumulation. Thus, reducing the incubation time necessary to accurately perform the 
assay without compromising sensitivity. 
Aptamer Dz System Preferentially Detects Oligomeric -SYN 
Of the three Dz systems evaluated for selectivity to oligomeric -SYN over the monomeric 
species (Figure 15), the BiDz and Tile Dz showed no selectivity; in fact, they showed a ~25% 
preference to the monomeric species when compared to oligomeric. However, the Aptamer Dz 
system showed ~10% preference to the oligomeric species and will be further optimized to 
increase its specificity. None of the systems demonstrated reactivity to thrombin, which was used 
at a concentration of 26 M, ten times the physiological plasma concentration. 
There are two possible explanations as to why the BiDz and Tile Dz systems exhibited 
higher selectivity to the monomeric species:  
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1. The sequences referenced in the literature that were adapted and modified for this 
study were not originally selected against oligomeric -SYN in the presence of a 
high-detergent buffer (such as that used for the Dz assays). Differences in salt and 
detergent concentrations can influence binding abilities of nucleotide sensors and as 
such may have caused a change in ligand affinity.  
2. The BiDz and Tile Dz systems require “splitting” of the analyte-binding region, 
whereas the Aptamer Dz system relied on use of whole aptamer sequences adapted 
from Ikebukro et al. “Splitting” of oligonucleotide constructs for Dz adaptation can 
dramatically influence the analyte binding abilities; such that even a single nucleotide 
difference in location can affect the signal output.  
The use of these Dz systems for protein detection is novel, and thus the data presented 
here illustrates proof-of-concept. Utilization of Dz diagnostics as presented in this work will lead 
to development of a proprietary oligonucleotide sequence for oligomeric -SYN detection.   
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CHAPTER THREE: PDI Disruption of Oligomeric -SYN 
Materials and Methods 
Recombinant PDI Deletion Construct Production 
To purify recombinant full-length PDI as well as the library of deletion constructs, each pET28 
bacterial expression vector (kindly provided by Dr. Kenneth Teter of University of Central 
Florida, Burnett School of Biomedical Sciences) was transformed into E. coli strain BL21 (New 
England Biolabs Ipswich, MA) . Overnight cultures were inoculated into Luria Muller broth with 
ampicillin selection (100 mg/ml) and grown to an optical density of 0.8 at 600 nm. Cultures were 
then induced at a final concentration of 2 mM IPTG at 37°C for four hours with shaking. Cells 
were pelleted at 6,000 rpm for twenty minutes at 4°C. Pellets were resuspended in extraction 
buffer (20 mM Tris-HCl pH 7.0, 300 mM NaCl). Cells were then lysed using lysozyme-based 
lysis buffer (extraction buffer, 0.1% Triton X-100, 1% sodium deoxycholate, 100 μg/ml 
lysozyme, and 0.1 μl/ml DNAse) followed by three, fifteen minute cycles of freezing (-80°C) 
and thawing (37°C). The lysate mixture was centrifuged at 12,000 RCF for thirty minutes at 4°C. 
The supernatant was collected and spiked with protease inhibitor cocktail (Roche Indianapolis, 
Indiana). Crude lysate was added to equilibrated talon resin slurry (Clontech Mountain View, 
CA) then agitated for thirty minutes at room temperature. The mixture was then centrifuged at 
700 RCF for five minutes. After removal of the supernatant, the resin was resuspended with 
wash buffer (extraction buffer, 600 mM NaCl, and 0.1% Triton X-100) and incubated at room 
temperature for fifteen minutes with agitation. The solution was centrifuged at 700 RCF for five 
minutes and supernatant collected; this process was repeated twice. Extraction buffer was used to 
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resuspend the washed resin and the solution was loaded into a gravity flow column. To elute the 
His-tagged proteins, a gradient of imidazole (10 mM, 20 mM, and 40 mM) in extraction 
extraction buffer was used. There were four rounds of elution per imidazole concentration in 500 
μl increments. Fractions were then denatured, electrophoresed via 10% SDS-PAGE, and 
visualized using a Coomassie brilliant blue staining (1.0 g coomassie brilliant blue, 50% [v/v] 
methanol, and 10% [v/v] glacial acetic acid) followed by destaining (40% [v/v] Methanol and 
10% [v/v] glacial acetic acid). 
pcDNA3.1 Cloning 
Primers were designed to contain 5’ BamHI and 3’ EcoRI cut sites for downstream digestion-
ligation reactions, along with a 5’ 6X Histidine tag (Table 2). PDI cDNA and deletion constructs 
were amplified using a standard amfiSure Taq polymerase master mix (GenDEPOT Barker, TX) 
using a 5°C gradient PCR for optimal purity. The cDNA was purified via UV transillumination 
and Zymoclean gel DNA recovery kit (Zymo research group Irvine, CA). cDNA and pcDNA3.1 
vector were double-digested using BamHI and EcoRI restriction endonucleases (Fermentas 
Thermo Scientific Grand Island, NY) at 37°C overnight. Following another round of gel 
extraction and purification, digested vector and insert were ligated overnight using T4 DNA 
Ligase (New England Biolabs Ipswich, MA) at 4°C. Ligation reactions were subsequently 
transformed into calcium chloride competent DH5α E. coli (New England Biolabs Ipswich, MA) 
using a heat shock regimen (4ºC for thirty minutes, 42°C for fifty seconds, 4°C for three minutes) 
followed by a one hour recovery stage in Super Optimal Broth with Catabolic repression (SOC) 
at 37°C before being plated on LB agar plates with ampicillin (100 mg/ml). Clones were pre-
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screened via colony PCR method to determine potential positive clones (Promega Madison, WI). 
Sanger sequencing was used to determine removal of N-terminal ER retention sequence 
(GENEWIZ South Plainfield, NJ). Plasmid DNA was then isolated in bulk via GeneJET Plasmid 
Miniprep kit (Thermo Fisher Scientific Waltham, MA). 
Cell Culture 
All cellular studies were performed in Human Embryonic Kidney 293T (HEK 293T) 
immortalized cell line in Dulbecco’s Modified Eagle’s Media with 10% fetal bovine serum 
(Atlanta Biologicals Flowery Branch, GA). Transfections were prepared by seeding cells such 
that they reached 50% confluency at the day of transfection. Transfections were performed using 
X-fect transfection reagent (Clontech Mountain View, CA) with a four-hour incubation period in 
serum-free media followed by a complete media change. 
PDI Overexpression  
Cells were transfected with 2.5 µg of recombinant pcDNA3.1 PDI or 2.5 µg of pcDNA3.1 empty 
vector and allowed to incubate for a forty-eight hour post transfection period before harvesting 
via trituration in 1X PBS with protease inhibitor cocktail. 
α-SYN Overexpression and Aggregation Induction for Biochemical Assay 
Cells were transfected with 2.5 µg pAAV-IRES-hrGFP-wt SNCA, 2.5 µg pAAV-IRES-hrGFP-
S42Y SNCA, and 2.5 µg pAAV-IRES-hrGFP empty vector (designed by the lab of Dr. Yoon-
Seong Kim of University of Central Florida, Burnett School of Biomedical Sciences). Cells were 
allowed to incubate for a forty-eight hour post-transfection period with routine media changes. 
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Approximately four hours prior to collection, cell media was spiked with 500 nM MG132. Cells 
were rinsed with PBS and collected by trituration in PBS spiked with protease inhibitor cocktail. 
Split Protein Complementation Assay 
Cells were triple transfected with 250 ng syn-hGLuc1 (SL1) and 250 ng syn-hGLuc (SL2) 
(kindly provided by Dr. Pamela McLean of Massachusetts General Hospital, Boston, MA) and 
either 500 ng of pcDNA3.1 vehicle or pcDNA3.1 PDI overexpression vectors in HEK 293T 
cells. Forty-eight hours post-transfection, cells were rinsed with 100 μl of PBS, and lysed by 
adding 50 μl of Cell Lysis Buffer (Pierce Biotechnology Rockford, IL) in each well and 
incubating for thirty minutes at room temperature with orbital shaking. Crude lysates were 
collected and spun down at 16,000 RCF for five minutes at room temperature. Supernatants were 
collected and protein concentration determined as previously mentioned. 20 μg normalized 
samples were loaded into a black-bottom 96 well plate and 50 μl of coelenterazine working 
solution (Pierce Biotechnology Rockford, IL) was added to each well before luminometry via 
EnVision Multilabel Reader (Perkin Elmer Waltham, MA). 
Immunoblotting 
Reducing SDS-PAGE 
Cells were harvested in PBS and lysed using radioimmunoprecipitation buffer (RIPA) and spun-
down at 14,000 RCF for fifteen minutes at 4°C. Supernatants were extracted, concentration 
determined via detergent compatible Lowry assay (BioRad Hercules, CA) and normalized. 
Samples were denatured by boiling for five minutes in 4X reducing Laemmli buffer ( 40% [v/v] 
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glycerol, 240 mM Tris-HCl pH 6.8, 8% SDS [w/v], 0.04% bromophenol blue [w/v], and 5% 
[v/v] beta-mercaptoethanol), followed by immediate cooling on ice and electrophoresed on a 
denaturing polyacrylamide gel. Following a Western transfer onto a 0.18 μm nitrocellulose 
membrane (BioRad Hercules, CA), the membrane was blocked in 5% milk in 0.1% TBS-T. 
Primary antibodies and dilutions included: primary anti-His Tag antibody (Santa Cruz 
Biotechnology Dallas, TX) at a 1:1,000 dilution and Syn-1 antibody (BD biosciences San Jose, 
CA) at a 1:500 dilution. Secondary antibodies and dilutions consisted of anti-mouse secondary 
antibody conjugated to HRP at a 1:5,000 dilution (Thermo Fisher Grand Island, NY). All 
primary antibody incubations occurred at 4°C overnight, while all secondary antibody 
incubations occurred at room temperature for one hour. Blots were developed using enhanced 
chemiluminescent reactions (ECL).  
Non-Reducing SDS-PAGE 
Cells were washed with PBS, collected by trituration, and resuspended in PBS-T spiked with 
EDTA-free protease inhibitor cocktail. To lyse the cells, the suspension was sonicated at 40 Hz 
two times for fifteen seconds each. Lysates were then spun down at 20,000 RCF for twenty 
minutes at 4°C and protein concentration determined via detergent compatible Lowry assay. 
After normalization, the samples were treated with 4X sample buffer, free of beta-
mercaptoethanol (1X PBS, 10% FBS, 1% BSA, 0.1% bromophenol blue) and denatured at 99°C 
for five minutes followed by cooling on ice. Samples were loaded onto a 5% SDS-PAGE gel 
with a 4% stacking gel and electrophoresed at 100 V for two hours. After electrophoresis, the gel 
was transferred to a 0.18 µm nitrocellulose membrane with the stacking gel intact and proteins 
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were transferred for two hours at 90 V at room temperature. After transfer, the membrane was 
fixed with 0.4% paraformaldehyde (PFA) for thirty minutes at room temperature, followed by a 
brief wash in 0.1% TBS-T and blocking with 5% skim milk. The membrane was incubated with 
primary Syn-1 antibody (BD biosciences San Jose, CA) at a 1:500 dilution per 20 µg of loaded 
protein overnight at 4°C with rocking. Following three, ten minute washes, the membrane was 
incubated with anti-mouse secondary antibody conjugated to HRP at a 1:5,000 dilution (Thermo 
Fisher Grand Island, NY) for one hour at room temperature with rocking. After another round of 
washing, detection proceeded through ECL reaction. 
 
Results and Discussion 
Full Length PDI and Deletion Constructs Purified for Downstream in vitro Assay 
Full-length PDI, as well as the abb’x and bb’x deletion constructs (Figure 16), were successfully 
transformed and purified from BL21 (Figure 17). Future work will consist of purification of 
several other deletion constructs (bb’xa’x and b’xa’c) as well as optimization of a Thioflavin T 
(ThT) assay.  
 ThT is a fluorogenic compound that upon interaction with amyloid fibers (i.e. oligomeric 
α-SYN) becomes fluorescent and can be quantified at an excitation/emission wavelength of 
450/482 nm, respectively. Through this technique, purified full-length and deletion constructs 
will be analyzed to ascertain which domain(s) are solely responsible for PDI’s chaperone activity 
and at what optimal ratio it functions to disrupt synucleinopathies in vitro. Furthermore, time 
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point optimization will occur to determine the range at which PDI, and appropriate deletion 
constructs, are able to function as a disaggregase to reverse preexisting α-SYN oligomers.  
PDI Inhibits α-SYN Aggregation in Live Cells as Reported by Complementation Assay 
Full-length PDI and the abb’x and bb’x deletion constructs were successfully cloned into the 
pcDNA3.1 mammalian expression system (Figure 18). The N-terminal ER retention sequence 
was successfully removed so as to target PDI expression to the cytosol; This deletion was then 
confirmed by Sanger sequencing and qualitatively analyzed via agarose gel electrophoresis 
(Figure 19). Western blot analysis of 293T lysates transfected with pcDNA3.1 PDI expression 
vector demonstrated successful translation under the CMV promoter (Figure 20).  
To monitor the preventative effects PDI has on α-SYN aggregation in live cells, a 
previously reported protein-fragment complementation assay (PCA) as communicated from 
McLean et al was used85. This system relies on two separate overexpression plasmids, each 
bearing a complete α-SYN expression sequence, tethered to either the N-sequence (AA1-93) or 
C-sequence (AA94-185) of a Gaussia luciferase (Gluc) gene (Figure 21). Upon aggregation of 
the α-SYN molecules, the N- and C-fragments are brought within close proximity to each other 
to create a functional Gluc protein, which can be quantified via traditional luminometry upon 
addition of the substrate coelenterazine. Quantification of PDI treatment in live cells using the 
split-complementation aggregation reporter assay revealed a ~25% decrease in luciferase signal, 
suggesting inhibition of α-SYN oligomerization in live cells (Figure 22). To support this 
analysis, a western blot of lysate samples revealed a controlled plasmid transfection paradigm 
(Figure 23). 
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Using a non-reducing SDS-PAGE, a live cell aggregation assay has been optimized 
wherein supramolecular oligomers of native, untagged α-SYN can be resolved via low 
percentage acrylamide gel to reveal “smearing” upstream of the 14 kDa monomeric α-SYN 
band. A lysate containing hyper-aggregative S42Y mutated α-SYN was used as a positive 
control, while non-transfected 293T was used to demonstrate strictly monomeric α-SYN as it 
would appear using this electrophoretic technique (Figure 24). With this technique, 
quantification of the smearing intensity both with and without PDI treatment will offer a 
biochemical assaying technique. This will be used to corroborate the split-complementation 
assay and evaluate potential differences in PDI treatment using untagged α-SYN (which may 
exhibit a different biochemical profile as compared to α-SYN that is tagged to the 20 kDa 
Gaussia luciferase protein).     
Future work will consist of repeating the split complementation luciferase assay using the 
deletion constructs to determine which domain is responsible for the chaperone activity and 
henceforth explored as a gene therapy. A tetracycline-inducible PDI expression cell line will be 
generated so as to characterize the extent of PDI’s reversal abilities in live cells. Furthermore, a 
modified non-reducing SDS-PAGE has been optimized and will be used to quantify oligomeric 
α-SYN species and PDI-mediated abrogation. Concomitantly, a live cell amyloid staining 
procedure coupled to flow cytometric analysis will be optimized to corroborate the findings 
presented by the split-complementation assay and SDS-PAGE biochemical assay.  
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CHAPTER FOUR: FIGURES AND TABLES 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Anatomical Distinctions Between the Substantia Nigra Pars Compacta in Patients with Parkinson’s 
Disease and Healthy Control   
http://www.umm.edu/health/medical/reports/articles/parkinsons-disease 
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Figure 2: Histological Profile of Intraneuronal Lewy Body  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Structural Representation and Biochemical Hotspots of alpha-Synuclein 
  
http://www.umm.edu/health/medical/reports/articles/parkinsons-disease 
Cross-sectional tissue stain from the Substantia Nigra illustrating Lewy 
Body. Melanin crystals appear as brown spots within the LB. 
http://journal.frontiersin.org/article/10.3389/fnins.2015.00059/full 
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Figure 4: alpha-Synuclein Aggregation Cascade 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://www.nature.com/nrn/journal/v14/n9/full/nrn3549.html 
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Figure 5: ssDNA Aptamer Secondary Structure  
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Figure 6: Tuerk and Gold SELEX Method for Aptamer Selection and Enrichment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Binary Deoxyribozyme Schematic  
ANALYTE 
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Figure 8: Tile Deoxyribozyme Platform Schematic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Aptamer Deoxyribozyme Schematic  
ANALYTE 
ANALYTE 
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Figure 10: Ribbon Model of Protein Disulfide Isomerase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Dot Blot Confirmation of Aptamer Specificity Before Deoxyribozyme Adaptation 
  
      2.0 μg         1.5 μg         1.0 μg            0.5 μg 
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Table 1: Oligonucleotides Used for Deoxyribozyme Generation 
  
aBHQ-1 – Black Hole Quencher1 bSD, standard desalting ciSp9, internal triethylene glycol spacer (IDT) 
dRibonucleotides are in lower case eoligo thymidine linkers are in italics. 
 
 
  
Name Sequence 5‘ 3‘a,b,c,d,e Purification b 
F_sub-1 CGGT ACA TTG TAG AAG TT AAG GTTFAM TCC TCg uCC CTG GGC 
A-BHQ1 
HPLC  
F_sub AAG GTTFAM TCC TCg uCCC TGG GCA-BHQ1 HPLC 
Hilt_T-
SO504  
CGGT ACA TTG TAG AAG TT CAG GGG TGG GCA AAG GGC GGT 
GGT G 
SD 
T-SO504 
complement
  
CAC CAC CGC CCT TTG CCC ACC CCT G  SD 
Dza 
(Syn)_RT_T-
SO504 
CAG GGG TGG GC /iSp9/A CAA CGA GAGGAAAC SD 
Dzb 
(Syn)_RT_T-
SO504 
CCA GGG A GG CTA GCT /iSp9/GGG CGG TGG TG SD 
T1 CTC TAC TGA CGT GCC G TTT 
CGTCGATACGATGCA  GTACTGTCGCAT TTT CTC TAC TGA CGT 
GCC G 
SD 
T2 CTC TAC TGA CGT GCC G TTT AGCTGATCACACT AGATTCTG TAG 
TGCATCGTATCGACG TTT CTC TAC TGA CGT GCC G 
SD 
T3 CTC TAC TGA CGT GCC G TTT ATGCGACAGTAC CCG ATC GTC ATG 
AGC ACC TAA CTT TTG GCC ATCA CCC CAC CAA CA AGC 
SD 
T4 CTC TAC TGA CGT GCC G TTT 
GTAACGACCGAT  G  AGTGTGATCAGCT TTT CTC TAC TGA CGT 
GCC G 
SD 
T6 CTC TAC TGA CGT GCC G 
TTTAGTTAGGTCTCA  GCATCATCGAGCCTGA TTT CTC TAC TGA 
CGT GCC G 
SD 
T7 G TAT TCG GTA TTA GAC CCA GTT T CCCAG TTT 
AGACCGTGAGCATTGA CAACTGGATC GC ATCGGTCGTTAC TTT 
CTC TAC TGA CGT GCC G 
SD 
T8 CTC TAC TGA CGT GCC G TTT TCAGGCTCGATGATGC 
AGTCTCAGGT CACTGAACTGGTAGCGTACC TTT CTC TAC TGA 
CGT GCC G 
SD 
T5 
(Dza_alpha 
syn)  
CAGGGGTGGGC /iSp9/A CAA CGA GAGGAAAC TTT CAG AAT CTC 
GAT CCA GTT GAC CTG AGA CTT GAC GAT CGG CAT  
SD 
Hook AA CTT CTA CAA TGT ACCG TTTTT CGG CAC GTC AGT AGA G SD 
Dza_ 508 
(full) 
GCCTGTGGTGTTGGGGCGGGTGCG /iSp18/A CAA CGA 
GAGGAAAC 
SD 
Dzb_508 
(full)  
CCA GGG A GG CTA GCT /iSp18/ 
GCCTGTGGTGTTGGGGCGGGTGCG 
SD 
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Figure 12: Average Raw Fluorescence Values for All Trials 
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Figure 13: Average Signal-to-Background Ratios of Deoxyribozyme Activity 
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Figure 14: Limit of Detection Curves for the Deoxyribozyme Platforms after 18-Hour Incubation 
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Figure 15: Selectivity Analysis for Each Deoxyribozyme Platform After 18-Hour Incubation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Protein Disulfide Isomerase Deletion Construct Library 
  
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17:Protein Disulfide Isomerase Deletion Construct Purification Scheme 
  
[Imidazole] 
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Figure 18: Cloned pcDNA3.1 PDI Mammalian Overexpression Vector 
 
 
Table 2: DNA Primers Used for the Cloning PDI and Appropriate Deletion Constructs  
Primer 
Name 
Sequence (5’3’) Tm ΔG° 
Universal 
Forward 
TTATGCGGATCCATGCATCACCATCACCACCATA 64.5 -1.65 
Full-length 
Reverse 
AATACGGAATTCTTACAGTTCATCTTTCACAGCTTTCT 58.6 -1.28 
x Reverse AATACGGAATTCTTAAGGCTGCTTGTCCCAGT 62.5 -0.97 
 
  
PDI 
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Figure 19: Agarose Gel of PDI Deletion Constructs Subcloned to pcDNA3.1 
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Figure 20: Western Blot Confirmation of PDI 
Expression in pcDNA3.1System 
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Figure 21: Split Complementation Luciferase Aggregation Reporter Schematic 
  Each construct (A and B) are expressed from separate co-transfected 
overexpression plasmids. As α-SYN aggregates, the tethered luciferase fragments 
are brought within close proximity of each other to create a functional luciferase 
gene. Lack of aggregation or transfection of only one plasmid will not produce a 
functional luciferase protein 
A) 
B) 
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Figure 22: Luciferase Values After PDI Coexpression with Luciferase Reporting System 
 
 
 
 
 
 
 
 
 
 
Figure 23: Western Blot Control of Split Complementation Triple Transfection 
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Figure 24: Modified SDS-PAGE for Live Cell Aggregation Monitoring 
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